IGFBP3 and colorectal cancer: For IGFBP3 -A202C, there is no significant association with colorectal cancer risk when all studies are pooled into a meta-analysis (CA vs. AA: OR = 0.99, 95% CI = 0.88–1.11; CC vs. AA: OR = 1.06, 95% CI = 0.92–1.22; dominant model: OR = 0.98, 95% CI = 0.88–1.09; recessive model: OR = 0.94, 95% CI = 0.84–1.05) (Table 2).